New Tool In Allegro CTMS@Site Allows For Easy Tracking Of Patient Recruitment Initiatives
MADISON, Wis., Nov. 7, 2012 /PRNewswire/ -- The fall release of Allegro CTMS@Site, the clinical trial management system (CTMS) built for investigator sites and research groups, is rich with new features that aim to ease the workload of busy site staff. One key enhancement, much-anticipated by prospects and customers alike, is the addition of patient recruitment campaign functionality.
Sites are faced with many options for patient recruitment. Ads may be placed on media outlets such as TV and radio, social media may be utilized, or sites may develop their own call or email lists. However, tracking the impact of the campaign, response rate, and actual enrollment from all these sources can be difficult. Even more challenging, is comparing those numbers to the total cost of the recruitment effort and understanding which recruitment methods generate the highest return on investment (ROI).
The new recruitment campaign functionality within Allegro CTMS@Site helps ensure that the appropriate level of contact has been made and the next steps are clearly defined. Site staff can clearly see the recruitment progression from initial contact with a patient through registering them to the protocol.In addition to traditional recruitment sources, Allegro CTMS@Site allows sites to leverage their existing patient registry to quickly and easily generate their own call or email lists for recruitment campaigns. Within the patient registry, potential matches can be identified on a number of factors that are best suited to the requirements of the protocol. By relying on their existing data, sites can spend their time reaching out to potential patients rather than gathering contact information. With the addition of patient recruitment campaigns to the already highly adept CTMS, sites are able to streamline and simplify their workflows, increase efficiency, learn from their successes and failures, and ultimately increase their ROI. With a clear understanding of the number of potential subjects contacted versus the number enrolled on the trial and the resources spent, sites gain more visibility into negotiating future recruitment budgets. Learn more about patient recruitment by downloading the solution brief. About the Allegro Research on Demand Product LineThe Allegro ® family of products are easy-to-use, intuitively designed, cloud-based systems that support clinical research operations excellence. Allegro CTMS@Site ® is designed exclusively for investigator sites and research groups. To set up a demonstration of Allegro CTMS@Site or to learn more, please contact Forte Research Systems. SOURCE Forte Research Systems, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV